The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
Effects of moderate salt restriction alone and in combination with cilazapril on office and ambulatory blood pressure.
The purpose of the present study was to examine the effects of salt-restriction alone and in combination with an angiotensin-converting enzyme ( ACE ) inhibitor ( cilazapril ) on both office and ambulatory blood pressure ( BP ) levels in free living subjects with elevated BP . The study was carried out in an out-patient setting with subjects recruited from occupational health care system mainly . After exclusions , 39 subjects ( 24 men , 15 women , aged 28 - 65 years ) with mildly to moderately elevated BP completed the study . After 3 months run-in period with placebo ( first month on normal-salt and the next 2 months on sodium-restricted diet ) the subjects were r and omised into either salt-restriction placebo or salt-restriction cilazapril ( 2.5 mg daily ) groups for 3 months . In the whole group , 24-h urinary sodium excretion decreased ( mean + /- s.d . ) from 198 + /- 60 to 112 + /- 59 mmol ( 4 weeks vs 24 weeks , P < 0.001 ) . Systolic and diastolic office BP decreased during the placebo-sodium-restriction phase ( -7.1 [ 95 % Cl -11.2 ; -3.0 ] and -4.2 [ 95 % Cl -6.6 ; -1.8 ] mm Hg for systolic and diastolic BP ) , and similarly the daytime ambulatory BP ( ABP ) was reduced during this period ( -2.8 [ 95 % Cl -5.2 ; -0.5 ] and -2.8 [ 95 % Cl -4.5 ; -1.2 ] mm Hg , systolic ( SBP ) and diastolic blood pressure ( DBP ) respectively ) . No changes were observed in the night time ABP . Addition of cilazapril to sodium-restriction enhanced significantly the office BP ( -13.2 , [ 95 % Cl -20.2 ; -6.2 ] , and -9.1 [ 95 % Cl -13.5 ; -4.7 ] ) and daytime ABP ( -5.9 , [ 95 % Cl -10.1 ; -1.8 ] and -5.3 , [ 95 % Cl -8.8 ; -1.9 ] ) reduction . Blood glucose , plasma insulin or serum lipids did not change during the study . Moderate sodium restriction seems to lower the office and daytime ABP levels in subjects with mild-to-moderate hypertension . The antihypertensive effect of cilazapril could be enhanced by sodium restriction
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .